Original Research

COVID-19 and Venous Thromboembolism Pharmacologic Thromboprophylaxis

Author and Disclosure Information

 

References

Conclusions

The COVID-19 pandemic has resulted in arguably the most challenging medical climate in the evidence-based medicine era. Until high-quality randomized controlled trials are published, the medical community is, in a sense, operating within a crucible of crisis having to navigate therapeutic policy with little certainty. This principle holds true for thromboprophylaxis in patients with COVID-19 despite the numerous advancements in this field over the past decade.

A review of societal guidance shows there is universal agreement with regards to supporting standard doses of pharmacologicalprophylaxis in acutely ill patients either when universally applied or guided by a RAM as well as the use of universal thromboprophylaxis in critically ill patients. All societies discourage the use of antiplatelet therapy for arterial thrombosis prevention and advocate for mechanical compression in patients with contraindications to pharmacologic anticoagulation. Beyond this, divergence between guidance statements begins to appear. For example, societies do not currently agree on the role and approach for extended pharmacologic prophylaxis postdischarge. The differences between societal guidance speaks to the degree of uncertainty among leading experts, which is considered to be the logical outworking of the current level of evidence. Regardless, these guidance documents should be considered the best resource currently available.

The medical community is fortunate to have robust societies that have published guidance on thromboprophylaxis in patients with COVID-19. The novelty of COVID-19 precludes these societal guidance publications from being based on high-quality evidence, but at the very least, they provide insight into how leading experts in the field of thrombosis and hemostasis are currently navigating the therapeutic landscape.

While this paper provides a summary of the current guidance, evidence is evolving at an unprecedented pace. Facilities and anticoagulation leads should be actively and frequently evaluating literature and guidance to ensure their practices and policies remain current.

Acknowledgments
This material is the result of work supported with resources and the use of facilities at the VA Tennessee Valley Healthcare System in Nashville/Murfreesboro.

Pages

Recommended Reading

Geriatric patients: My three rules for them
Federal Practitioner
AHA issues new scientific statement on heart health for LGBTQ adults
Federal Practitioner
Female cardiac advantage essentially lost after MI
Federal Practitioner
Fecal transplant linked to reduced C. difficile mortality
Federal Practitioner
Popularity of virtual conferences may mean a permanent shift
Federal Practitioner
Red hair in women linked to elevated CRP levels in Nurses’ Health Study
Federal Practitioner
TDF preferred in PrEP for Blacks and women, studies indicate
Federal Practitioner
Novel drug slows progression of diabetic kidney disease
Federal Practitioner
Health sector has spent $464 million on lobbying in 2020
Federal Practitioner
Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients
Federal Practitioner